PIPELINE

We target autoinflammatory and autoimmune diseases with high unmet medical need for which only  limited treatment options exist. This includes Graft-versus-Host Disease (GvHD) and multiple sclerosis (MS).

Current Status

CELL THERAPIES

Development

Preclinical

Phase 1

Phase 2

Phase 3

Devel.
Preclinic.
Ph. 1
Ph. 2
Ph. 3
Actileucel | GvHD
/
Actileucel | Multiple Sclerosis

BIOLOGICS

Development

Preclinical

Phase 1

Phase 2

Phase 3

Devel.
Preclinic.
Ph. 1
Ph. 2
Ph. 3
Treg activator | Autoimmune diseases

Actileucel
(treatment of MS)

Allogeneic cell therapy.

Treg are known to have tissue-reparing capability and to have positive impact on MS.

With own research ActiTrexx has gathered comprehensive data to support the application of Actileucel for the treatment of MS.

Actileucel
(prevention of GvHD)

Allogeneic cell therapy.

Ongoing clinical phase Ib/II trial to explore safety and feasibility of Actileucel early after HSCT. The trial is being performed in two German clinical sites and is expected to deliver first results by Q1/2025 (EudraCT 2021-006490-32).

Actileucel has received orphan drug designation (ODD) for use after stem cell transplantation by EMA and FDA.

Biologic
Treg Activator

Biologic.

The recombinant protein Treg Activator binds to CD4 and specifically activates Treg.

The Treg Activator is being developed for in-vivo activation of the patient’s own Treg to treat autoimmune diseases. The preclinical development is ongoing.